In addition to nonsteroidal anti-inflammatory drugs(NSAIDs) and lifestyle modifications, targeting specific cytokines through receptor antagonists, such as IL-6 inhibitors and TNF-α inhibitors, has shown promise in reducing inflammation and improving symptoms of depression and anxiety in some clinical trials. The gene discussed is IL6; the disease is depressive symptom measurement.